image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
Piper Sandler 34th Annual Healthcare Conference
November 30, 2022 at 4:30 PM EST
Credit Suisse Investor Conference
November 8, 2022 at 11:25 AM EST
Baird's 2022 Global Healthcare Conference
September 13, 2022 at 10:50 AM EDT
Wells Fargo Healthcare Conference
September 7, 2022 at 4:15 PM EDT
2022 RBC Capital Markets Global Healthcare Conference
May 18, 2022 at 11:00 AM EDT
21st Annual Needham Virtual Healthcare Conference
April 11, 2022 at 2:15 PM EDT
2nd Guggenheim Targeted Protein Degradation Day
March 16, 2022 at 11:00 AM EDT
32nd Annual Oppenheimer Healthcare Conference
March 15, 2022 at 4:00 PM EDT
11th Annual SVB Leerink Global Healthcare Conference
February 17, 2022 at 3:40 PM EST
Corporate Presentations
Scientific Presentation